← Back to Analyst Consensus 
XLO Buy
Xilio Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 5
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 21, 2026 | Raymond James | initiate | — → Outperform | — | 54% |
| Aug 6, 2025 | Leerink Partners | initiate | — → Outperform | $2 | 50% |
| Nov 8, 2024 | Raymond James | maintain | Outperform → Outperform | $4 | 54% |
| May 30, 2023 | Chardan Capital | reiterate | Buy → Buy | $7 | 47% |
| May 11, 2023 | Chardan Capital | reiterate | — → Buy | $7 | 47% |
| Jan 27, 2023 | Morgan Stanley | maintain | — → Overweight | $10 | 54% |
| Dec 21, 2022 | Chardan Capital | initiate | — → Buy | $7 | 47% |
| Nov 10, 2022 | Raymond James | maintain | — → Outperform | $13 | 54% |
| Aug 10, 2022 | Morgan Stanley | maintain | — → Overweight | $20 | 54% |
| Jan 10, 2022 | HC Wainwright & Co. | initiate | — → Buy | $36 | 44% |
| Nov 16, 2021 | Raymond James | initiate | — → Outperform | $31 | 54% |
| Nov 16, 2021 | Cowen & Co. | initiate | — → Outperform | $0 | — |
| Nov 16, 2021 | Morgan Stanley | initiate | — → Overweight | $32 | 54% |
Price Target Trend
Mar 30, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days